JonesResearch analyst Soumit Roy lowered the firm’s price target on Enliven (ELVN) to $27 from $36 and keeps a Buy rating on the shares. The company’s abstract from the Phase 1 late line chronic myeloid leukemia trial with ELVN-001 “was met with a lukewarm initial stock reaction that weakened over time,” the analyst tells investors in a research note. The firm says that even though ELVN-001 showed efficacy and safety profile inline with the September 2024 update with two-times the patient population, the market treated the stock with a sell on news approach. Jones sees ELVN-001 performing at least inline with Novartis’ Scemblix.

Confident Investing Starts Here:

Quickly and easily unpack a company's performance  with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox  with TipRanks' Smart Value Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on ELVN:

Disclaimer & DisclosureReport an Issue

Enliven Therapeutics’ ELVN-001: Promising Competitor in the $3 Billion Late Line CML Market Enliven Therapeutics Reports Q1 Results and Pipeline Progress Enliven price target raised to $40 from $39 at H.C. Wainwright Enliven Therapeutics: Strategic Focus and Promising Developments Justify Buy Rating Positive Buy Rating for Enliven Therapeutics Driven by Promising Phase 1 Results of ELVN-001 in CML

View Comments